{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:30:46Z","timestamp":1785403846508,"version":"3.56.0"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Assessments of chimeric antigen receptor (CAR) T-cell pharmacokinetics by flow cytometry (FC) and a droplet digital PCR (ddPCR) assay were compared in adult patients with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL) following treatment with obecabtagene autoleucel (obe-cel) in the phase Ib\/II FELIX study (NCT04404660). CAR T-cell persistence and B-cell aplasia (BCA) were then correlated with event-free survival (EFS). Peripheral blood (PB) samples collected from 127 obe-cel\u2013infused patients were tested by FC and ddPCR. The Spearman correlation coefficient was used to measure the correlation between the number of CAR T\u2013positive cells by FC and ddPCR. The impact of CAR T-cell persistence and BCA (B cells &amp;lt;20 cells\/\u03bcL by FC in PB) on EFS was assessed using Cox proportional hazards regression. ddPCR was observed to statistically correlate with both the surface (0.60, P &amp;lt; 0.0001) and intracellular FC assays (0.74, P &amp;lt; 0.0001). A higher sensitivity for detecting CAR T\u2013cell positive samples was observed with ddPCR, with 58.8% and 41.3% of samples negative by surface and intracellular FC, respectively, being positive by ddPCR. Loss of CAR T-cell persistence (HR, 2.7; 95% CI, 1.4\u20135.4) and, to a lesser degree, B-cell recovery (HR, 1.7; 95% CI, 0.7\u20133.8) as time-dependent variables and at month 3 were associated with poorer EFS. ddPCR demonstrated enhanced sensitivity over FC methods for detection of obe-cel persistence. Additionally, ongoing persistence and BCA were associated with longer EFS and may be taken into consideration, together with clinical parameters, in informing decision making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In patients with R\/R B-ALL treated with obe-cel, ddPCR assessment of CAR transgene levels produced results consistent with FC while providing superior sensitivity. ddPCR-detected CAR T-cell persistence at month 3 and at any time after infusion correlated with longer EFS versus loss of persistence, therefore potentially informing clinical decision making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0756","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:38:26Z","timestamp":1780605506000},"page":"1681-1692","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed\/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4901-5858","authenticated-orcid":false,"given":"Claire","family":"Roddie","sequence":"first","affiliation":[{"name":"1University College London Cancer Institute, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4485-2611","authenticated-orcid":false,"given":"William","family":"Day","sequence":"additional","affiliation":[{"name":"2Autolus Therapeutics, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6611-0914","authenticated-orcid":false,"given":"Meera","family":"Raymond","sequence":"additional","affiliation":[{"name":"2Autolus Therapeutics, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5630-6074","authenticated-orcid":false,"given":"Deborah","family":"Cluxton","sequence":"additional","affiliation":[{"name":"2Autolus Therapeutics, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0080-6594","authenticated-orcid":false,"given":"Jason","family":"Caulfield","sequence":"additional","affiliation":[{"name":"2Autolus Therapeutics, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8932-5789","authenticated-orcid":false,"given":"Heather","family":"Dainton-Smith","sequence":"additional","affiliation":[{"name":"2Autolus Therapeutics, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7958-7587","authenticated-orcid":false,"given":"Brooke","family":"McElwee","sequence":"additional","affiliation":[{"name":"3Autolus Therapeutics, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6173-1760","authenticated-orcid":false,"given":"Yanqing","family":"Hu","sequence":"additional","affiliation":[{"name":"3Autolus Therapeutics, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-8484","authenticated-orcid":false,"given":"Karamjeet S.","family":"Sandhu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope National Medical Center 4 , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4940-639X","authenticated-orcid":false,"given":"Eleni","family":"Tholouli","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03kr30n36","id-type":"ROR","asserted-by":"publisher"}],"name":"Manchester Royal Infirmary 5 , Manchester, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-5879","authenticated-orcid":false,"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043mz5j54","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California San Francisco 6 Hematology, Blood and Marrow Transplantation, and Cellular Therapy Program, , San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-3864","authenticated-orcid":false,"given":"Paul","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"7Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1085-3463","authenticated-orcid":false,"given":"Deborah","family":"Yallop","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01n0k5m85","id-type":"ROR","asserted-by":"publisher"}],"name":"King\u2019s College Hospital NHS Foundation Trust 8 , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-7969","authenticated-orcid":false,"given":"Pere","family":"Barba","sequence":"additional","affiliation":[{"name":"9Hospital Universitari Vall d\u2019Hebron-Universitat Aut\u00f3noma de Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-2578","authenticated-orcid":false,"given":"Manuel","family":"Guerreiro","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ar2v535","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitari i Polit\u00e8cnic La Fe 10 , Valencia, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5346-6299","authenticated-orcid":false,"given":"Jean A.","family":"Yared","sequence":"additional","affiliation":[{"name":"11University of Maryland, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8566-8927","authenticated-orcid":false,"given":"Katharine","family":"Hodby","sequence":"additional","affiliation":[{"name":"12University Hospital Bristol, Bristol, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6021","authenticated-orcid":false,"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"13Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8537-0577","authenticated-orcid":false,"given":"Wolfram","family":"Brugger","sequence":"additional","affiliation":[{"name":"14Autolus Therapeutics, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4363-0520","authenticated-orcid":false,"given":"Pierre","family":"Lao-Sirieix","sequence":"additional","affiliation":[{"name":"2Autolus Therapeutics, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3979-9273","authenticated-orcid":false,"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/024mw5h28","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Chicago 15 The David and Etta Jonas Center for Cellular Therapy, , Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 16 Department of Medical Oncology, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 17 , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-5130","authenticated-orcid":false,"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 18 , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026071504525049500_bib1","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"2026071504525049500_bib2","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"2026071504525049500_bib3","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026071504525049500_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2026071504525049500_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"2026071504525049500_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2026071504525049500_bib7","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood.2023022922","article-title":"The present and future of CAR T-cell therapy for adult B-cell ALL","volume":"145","author":"Rampotas","year":"2025","journal-title":"Blood"},{"key":"2026071504525049500_bib8","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026071504525049500_bib9","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"2026071504525049500_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"2026071504525049500_bib11","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"2026071504525049500_bib12","doi-asserted-by":"crossref","first-page":"23024","DOI":"10.1038\/s41598-023-48528-0","article-title":"Solving the mystery of the FMC63-CD19 affinity","volume":"13","author":"Seigner","year":"2023","journal-title":"Sci Rep"},{"key":"2026071504525049500_bib13","article-title":"Obecabtagene autoleucel prescribing information","author":"FDA","year":"2024"},{"key":"2026071504525049500_bib14","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"key":"2026071504525049500_bib15","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026071504525049500_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"2026071504525049500_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fmolb.2020.00084","article-title":"Digital-droplet PCR for quantification of CD19-directed CAR T-cells","volume":"7","author":"Mika","year":"2020","journal-title":"Front Mol Biosci"},{"key":"2026071504525049500_bib18","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026071504525049500_bib19","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.3390\/ijms24065688","article-title":"CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026071504525049500_bib20","doi-asserted-by":"crossref","first-page":"1615212","DOI":"10.3389\/fimmu.2025.1615212","article-title":"Tracing the development of CAR-T cell design: from concept to next-generation platforms","volume":"16","author":"Alsaieedi","year":"2025","journal-title":"Front Immunol"},{"key":"2026071504525049500_bib21","doi-asserted-by":"crossref","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"key":"2026071504525049500_bib22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28\u2212 or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"2026071504525049500_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/MOH.0000000000000685","article-title":"Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia","volume":"28","author":"Qayed","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"2026071504525049500_bib24","doi-asserted-by":"crossref","first-page":"110797","DOI":"10.1016\/j.compbiomed.2025.110797","article-title":"Healthy B cells: allies or adversaries of CAR-T cell immunotherapy?","volume":"196","author":"Paix\u00e3o","year":"2025","journal-title":"Comput Biol Med"},{"key":"2026071504525049500_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2026071504525049500_bib26","doi-asserted-by":"crossref","first-page":"830773","DOI":"10.3389\/fimmu.2022.830773","article-title":"Monitoring of circulating CAR T cells: validation of a flow cytometric assay, cellular kinetics, and phenotype analysis following tisagenlecleucel","volume":"13","author":"Peinelt","year":"2022","journal-title":"Front Immunol"},{"key":"2026071504525049500_bib27","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.3390\/cells10113208","article-title":"Sensitivity and specificity of CD19.CAR-T cell detection by flow cytometry and PCR","volume":"10","author":"Schanda","year":"2021","journal-title":"Cells"},{"key":"2026071504525049500_bib28","doi-asserted-by":"crossref","first-page":"8556","DOI":"10.3390\/ijms25168556","article-title":"A comprehensive ddPCR strategy for sensitive and reliable monitoring of CAR-T cell kinetics in clinical applications","volume":"25","author":"Wiedemann","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026071504525049500_bib29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the Human Immunology Project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"2026071504525049500_bib30","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3390\/ijms25052673","article-title":"Unlocking predictive power: quantitative assessment of CAR-T expansion with digital droplet polymerase chain reaction (ddPCR)","volume":"25","author":"Galli","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026071504525049500_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jmoldx.2020.02.007","article-title":"Detection and quantification of chimeric antigen receptor transgene copy number by droplet digital PCR versus real-time PCR","volume":"22","author":"Lou","year":"2020","journal-title":"J Mol Diagn"},{"key":"2026071504525049500_bib32","doi-asserted-by":"crossref","first-page":"e70247","DOI":"10.1002\/hem3.70247","article-title":"Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: an international consensus statement","volume":"9","author":"Lamble","year":"2025","journal-title":"Hemasphere"},{"key":"2026071504525049500_bib33","doi-asserted-by":"crossref","first-page":"658314","DOI":"10.3389\/fimmu.2021.658314","article-title":"Advanced flow cytometry assays for immune monitoring of CAR-T cell applications","volume":"12","author":"Blache","year":"2021","journal-title":"Front Immunol"},{"key":"2026071504525049500_bib34","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/cancers12061684","article-title":"A clinically applicable approach to the classification of B-cell non-Hodgkin lymphomas with flow cytometry and machine learning","volume":"12","author":"Gaidano","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026071504525049500_bib35","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/2767-9764.CRC-23-0357","article-title":"Spectral flow cytometry methods and pipelines for comprehensive immunoprofiling of human peripheral blood and bone marrow","volume":"4","author":"Spasic","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026071504525049500_bib36","doi-asserted-by":"crossref","first-page":"1152498","DOI":"10.3389\/fimmu.2023.1152498","article-title":"Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies","volume":"14","author":"Garc\u00eda-Calder\u00f3n","year":"2023","journal-title":"Front Immunol"},{"key":"2026071504525049500_bib37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cyto.a.24676","article-title":"Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction","volume":"103","author":"Cheng","year":"2023","journal-title":"Cytometry A"},{"key":"2026071504525049500_bib38","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jmoldx.2022.04.013","article-title":"A new view on minimal residual disease quantification in acute lymphoblastic leukemia using droplet digital PCR","volume":"24","author":"Schwinghammer","year":"2022","journal-title":"J Mol Diagn"},{"issue":"Suppl 1","key":"2026071504525049500_bib39","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S1525-0016(16)33083-0","article-title":"ASGCT 19th annual meeting: abstracts","volume":"24","author":"Eyquem","year":"2016","journal-title":"Mol Ther"},{"key":"2026071504525049500_bib40","doi-asserted-by":"crossref","first-page":"e0085321","DOI":"10.1128\/spectrum.00853-21","article-title":"Development of droplet digital PCR-based assays to quantify HIV proviral and integrated DNA in brain tissues from viremic individuals with encephalitis and virally suppressed aviremic individuals","volume":"10","author":"Chung","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2026071504525049500_bib41","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"2026071504525049500_bib42","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026071504525049500_bib43","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2022016937","article-title":"How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL","volume":"141","author":"Myers","year":"2023","journal-title":"Blood"},{"key":"2026071504525049500_bib44","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/oncolo\/oyac163","article-title":"FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0756\/3801695\/crc-25-0756.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1681\/3811802\/crc-25-0756.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1681\/3811802\/crc-25-0756.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:53:03Z","timestamp":1784105583000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/7\/1681\/786629\/CAR-T-cell-Kinetics-Persistence-and-Clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0756","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32991847","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991868","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991859","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991877","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991865","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991853","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991856","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991844","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991850","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991874","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991871","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991862","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32991880","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8596243","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}